Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context

INTRODUCTION: DNA‐based TLR9 agonists are potent activators of the immune system. ProMune® and dSLIM® belong to different families of TLR9 agonists and both have been established as cancer immunotherapeutics in clinical proof‐of‐concept studies. Unfortunately, ProMune® failed in pivotal oncological...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapp, Kerstin, Schneider, Jacqueline, Schneider, Lisa, Gollinge, Nadine, Jänsch, Stefanie, Schroff, Matthias, Wittig, Burghardt, Kleuss, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134728/
https://www.ncbi.nlm.nih.gov/pubmed/27980779
http://dx.doi.org/10.1002/iid3.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134728/
https://www.ncbi.nlm.nih.gov/pubmed/27980779
http://dx.doi.org/10.1002/iid3.126

Ejemplares similares